|
Found 53 result(s) FROM 1963 pages containing the term 'ACL tear'.
Wednesday Mar 31, 2010
Fibromyalgia Symptoms May be Alleviated by Short Bursts of Physical Activity
Lifestyle physical activity intervention may reduce fibromyalgia symptoms and improve physical function...
Friday Oct 16, 2009
EMG Finds “High Risk” Zone for ACL Tears in Female Athletes
Reduced semitendinosus (ST) and elevated vastus lateralis (VL) activity increase the risk of ACL tear—and taking bits from the ST for ACL repair is probably a mistake...
Thursday Oct 08, 2009
Second Knee Surgery Common Among Young Patients
Young people who have surgery to repair a damaged ACL will likely need additional surgery in the future...
Tuesday Sep 29, 2009
Fibromyalgia Goes Legit
Better understanding of the brain chemistry anomalies in fibromyalgia have paved the way toward more effective treatments for this pain disorder...
Friday Apr 24, 2009
Knee Laxity Tied to Menstrual Cycle
Female athletes are 2 to 8 times more likely to injure their ACL ligaments than men, and 3 new studies say that knee joint laxity related to the menstrual cycle is to blame...
Wednesday Feb 25, 2009
ACL Repairs Becoming More Common in Kids, Don't Shorten NFL Careers
Anterior cruciate ligament (ACL) reconstruction is becoming more common in school-age athletes and needs longer healing time than is sometimes allowed, but it need not jeopardize a professional sports career...
Tuesday Feb 24, 2009
New Program Prevents ACL Tears In High School Girls' Sports
A pilot program to prevent anterior cruciate ligament (ACL) tears among female high school athletes has been so successful that it will be expanded to over 11,000 high school athletes...
Wednesday Dec 03, 2008
Data from KANON Patients Blow Hole in ACL Repair
Surgical reconstruction was not better than training alone for restoring muscle strength and function after ACL injury…
Thursday Nov 06, 2008
Falls Are Leading Cause of Injury to Seniors
The elderly have an increased risk of falls and bone injuries, but certain preventive measures can help protect them…
Thursday Oct 16, 2008
Novartis Reports Once-Yearly Aclasta® Approved in EU to Treat Osteoporosis in Men; Label to Include Reduction of New Fractures Following Hip Fracture in Men and Postmenopausal Women
The European Commission followed the US FDA in approving once-yearly Aclasta for the treatment of osteoporosis in men who are at increased risk of fractures, and has broadened the drug’s label to include reduction of new fractures in men and postmenopausal women with osteoporosis who have recently suffered a hip fracture...
Thursday Sep 04, 2008
Omeros Enters Into Agreement With Affitech for Anti-inflammatory Therapeutics, Awaits Phase III Clinical Trial Results for Agent
Omeros Corp and Affitech AS have entered into an agreement for the discovery and development of fully human antibodies for Omeros’ MASP-2, which mediates activation of the complement system via the lectin pathway...
Friday Aug 29, 2008
Ligaments Tie Together OA Pathology
Ligaments are emerging as the key to understanding why osteoarthritis develops in nontraumatized joints...
Thursday Aug 14, 2008
Are More Vioxx-Like Drug Catastrophes Inevitable?
Sociologist predicts growing numbers of drug safety disasters because of fatal flaws in the way new drugs are tested and marketed…
Tuesday Jun 10, 2008
Novartis’ Once-Yearly Reclast® Injection 5 mg Receives Revised US Label; Indication to Include Prevention of Fractures After a Hip Fracture
The FDA has broadened the indication for once-yearly Reclast® (zoledronic acid) for postmenopausal osteoporosis to include the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture...
Friday May 23, 2008
Iatrogenic Problems Reported in Low Back Pain, Osteoporosis Patients at AACE Meeting
Cases of iatrogenic Cushing's syndrome (CS) from intra-articular triamcinolone and iatrogenic hypercalcemia from combined teriparatide-hydrochlorothiazide were reported at the American Association of Clinical Endocrinologists 2008 meeting...
Tuesday May 20, 2008
Warner Chilcott, LEO Pharma Report FDA Approves Taclonex Scalp®, a Once-Daily Therapy for Treatment of Moderate-to-Severe Scalp Psoriasis
The US FDA has approved the new drug application for Taclonex Scalp® topical suspension for the treatment of moderate-to-severe psoriasis vulgaris of the scalp in adults...
Tuesday May 13, 2008
More than Half of US Diabetics Have Arthritis
Arthritis afflicts more than half of diabetes patients in the US, making exercise difficult…
Tuesday Apr 29, 2008
Women Risk Bone Loss After Knee Surgery
Women who underwent surgery to repair a torn ACL suffered significant bone loss surrounding the knee…
Tuesday Apr 15, 2008
Novartis Says Aclasta Better at Boosting Bone Mass
Novartis reported study results indicating a once-yearly infusion of Aclasta is more effective than risedronate at increasing bone mass in patients taking steroids...
Friday Mar 07, 2008
ACL Tears Should Be Repaired Within 12 Weeks of Injury
ACL reconstruction should be done within 12 weeks of injury to avoid irreparable meniscus damage...
Friday Mar 07, 2008
Sports Doctors Urge for More Injury Prevention in Women Athletes
Sex matters in sports injuries, and more attention to special problems of women athletes is needed...
Tuesday Feb 19, 2008
Sensitivity to Implant Materials in Patients With Total Knee Arthroplasties
Total knee arthroplasty patients may experience increased sensitization, which can negatively impact the outcome of the implant...
Tuesday Feb 19, 2008
Big-Time Injury Strikes Little Players
An increasing number of child and adolescent athletes are being diagnosed with torn ACLs...
Friday Jan 18, 2008
Third Study Finds No Gain to Bracing Knee After ACL Reconstruction
Functional knee braces are widely used for patients returning to sports or other activity following ACL reconstruction, but a randomized, controlled trial found that the costly braces are no better than neoprene sleeves—and probably no better than not bracing at all...
Saturday Nov 10, 2007
More Fallout From the COX-2 Debacle: Increasing Rates of Serious GI Complications
Physicians need to be more vigilant about prescribing proton pump inhibitors (PPIs) to their arthritis patients who take traditional nonsteroidal anti-inflammatory drugs (NSAIDs), because the number of serious gastrointestinal complications is on the rise since the COX-2 drugs fell from grace...
Friday Oct 12, 2007
Novartis' Aclasta® Receives EU Approval as First Once-Yearly Treatment for Postmenopausal Osteoporosis
Novartis Pharmaceuticals AG announced that Aclasta® (zoledronic acid 5 mg) has received EU approval as the first once-yearly treatment for women with postmenopausal osteoporosis...
Wednesday Sep 19, 2007
Anticytokine Shots May Aid Healing Following Knee Injuries
Shooting TNF inhibitors or IL-1 blockers directly into the joint may help promote healing following meniscal tears…McNulty AL, et al. Arthritis Rheum. 2007;56:doi:10.1002/art [Epub ahead of print].
Monday Sep 10, 2007
Jury Out on Whether Surgical Repair of ACL Tears Staves Off OA
Little convincing evidence supports surgical repair of the anterior cruciate ligament or meniscus as a way of preventing OA, but the problem may lie in the way the studies have been done, not in the surgery…Lohmander LS, et al. Am J Sports Med. 2007 Aug 29; doi: 10.1177/0363546507307396 [Epub ahead of print].
Monday Aug 27, 2007
Harkness Dance Medicine Head Urges Clinicians to Prepare for the "High School Musical 2" Generation
Musicals are back, dance classes are filled, clinicians are facing more dancers or former dancers with musculoskeletal problems, and dance medicine experts are urging clinicians to heed the beat of dancing feet...
Monday Aug 20, 2007
Novartis' Once-Yearly Reclast® Receives US FDA Approval for Women With Postmenopausal Osteoporosis
Novartis Pharmaceuticals Corp announced that its once-yearly, 15-minute infusion treatment of Reclast® (zoledronic acid) injection has been approved by the US FDA for women with postmenopausal osteoporosis...
Tuesday Jul 24, 2007
Novartis Receives Positive Opinion Supporting EU Approval for Aclasta® as the First Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Novartis Pharmaceuticals AG announced that it has been informed by the European Medicines Agency that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the marketing application for the use of Aclasta®.
Wednesday Jul 18, 2007
Brain Function Linked to "Noncontact" Knee Injuries
Differences in brain function may predispose athletes to ACL injury…Swanik CB, et al. Am J Sports Med. 2007;35:943-948.
Monday May 07, 2007
Novartis' Once-Yearly ReclastR Significantly Reduces Bone Fractures in Women With Postmenopausal Osteoporosis
Novartis Pharmaceuticals Corp announced that its once-yearly treatment of ReclastR (zoledronic acid) significantly reduces the incidence of all types of osteoporotic bone fractures in women with postmenopausal osteoporosis...
Wednesday Nov 15, 2006
Is Resection Necessary? Meniscal Tears Rarely Cause Pain
Meniscal resection may do little to relieve pain among older patients with knee osteoarthritis (OA), as meniscal tears are common but rarely cause any symptoms... Englund M, et al. Presented at ACR 2006 Meeting.
Monday Sep 18, 2006
Novartis' Once-Yearly Reclast Investigational Infusion Osteoporosis Treatment Significantly Cuts Risk of Spine and Hip Fractures in Postmenopausal Women
Novartis Pharmaceuticals Corporation announced that phase III data presented at the 28th Annual meeting of the American Society for Bone and Mineral Research (ASBMR), September 15–19, 2006, in Philadelphia, Pa, demonstrated that its investigational, once-yearly bisphosphonate 15-minute infusion treatment, Reclast® (zoledronic acid) 5 mg, was highly effective at reducing the incidence of bone fracture in women with postmenopausal osteoporosis across the most common fracture sites—hip, spine, and nonspine (with the exception of face, fingers, and toes)—with sustained effect over 3 years.
Thursday Aug 17, 2006
Superagonist Trial Hit By Cytokine Storm
The six patients who nearly died in a phase I trial of an experimental anti-CD28 monoclonal antibody being developed as a rheumatoid arthritis treatment were injured by "cytokine storms" triggered by the new drug, and the head of the intensive care unit where their lives were saved thinks this demonstrates that a new approach to testing biologic agents is needed....Suntharalingam G, et al. N Engl J Med. 2006; August 14; [Epub ahead of print].
Thursday Aug 10, 2006
Michigan Researchers to Study ACL Injuries, Bone Bruises, in Knee OA
Anterior cruciate ligament (ACL) injuries are common in young athletes and often lead to later knee osteoarthritis (OA). A new prospective study will try to determine whether bone bruises add to that risk.
Wednesday Aug 02, 2006
Fear of Pain Robs Arthritis Patients of Chance for Pain-Relieving Exercise
Fear of pain is a major reason people with arthritis avoid exercise, and many are unaware that regular exercise can reduce pain and prevent disability. …Wilcox, S, et al. Arthritis Care Res. August 2006; DOI: 10.1002/art.22098
Tuesday Jun 27, 2006
Bosentan Prevents Digital Ulcers, Improves Heart Function in Systemic Sclerosis
Bosentan reduces digital ulcer risk and improves heart function in systemic sclerosis patients... Allanore Y, et al. Presented at: EULAR 2006 Meeting; June 21–34, 2006; Amsterdam, The Netherlands. Abstract OP0120.
Wednesday Jun 14, 2006
MRI Reveals Little in Low Back Pain
Routine use of MRI in early episodes of low back pain is probably a mistake... Carragee E. Presented at: American Pain Society 25th Annual Meeting; May 3–6, 2006; San Antonio, Tex.
Tuesday May 02, 2006
Exercise, Weight Loss Can Reverse Frailty in Obese Elderly
Diet-induced weight loss and exercise training can significantly strengthen and protect obese older adults and should be considered primary therapy in frail obese older patients... Villareal DT, et al. Arch Intern Med. 2006;166:860-866.
Monday Apr 17, 2006
LEO Pharma and Warner Chilcott Launch Taclonex®, a Dual-Action, Once-Daily, Topical Therapy for Plaque Psoriasis in the US
Warner Chilcott, of Rockaway, NJ, and LEO Pharma A/S, of Copenhagen, Denmark, announced that Taclonex® (calcipotriene 0.005% and betamethasone dipropionate 0.064%) is now available for prescription in the US...
Thursday Jan 12, 2006
Three Months of Bosentan Therapy Improves Function in SSc-PAH Patients
Three Months of Bosentan Therapy Improves Function in SSc-PAH Patients
Monday Nov 07, 2005
Underpowered Randomized Clinical Trials Common in Rheumatology
A new literature review reports that underpowered randomized clinical trials (RCTs), which have been criticized as unethical and inadequate tests of an underlying hypothesis, accounted for approximately 21% of phase III RCTs of adult rheumatologic diseases published in English during 2001–2002 ... Keen HI, et al. J Rheum. 2005;32:2083-2088.
Friday Nov 04, 2005
Study Provides Additional Clues to the Causes of Systemic Sclerosis and the Potential Efficacy of Paclitaxel
New research in a murine model points to the ability of low-dose paclitaxel (Taxol®) to modulate transforming growth factor-beta (TGF-ß) and lessen fibrosis in systemic sclerosis patients, findings that also provide additional clues to the pathogenesis of the disease... Liu X, et al. PloS Med. 2005;2:e354
Tuesday Sep 13, 2005
Two New Treatments Show Promise in Paget's Disease
Zoledronic acid and osteoprotegerin found to be promising new therapies for the management of Paget's disease... Reid IR, et al. N Engl J Med. 2005;353:898-908; Cundy MD, et al. N Engl J Med. 2005;353:918-923.
Friday Aug 19, 2005
Stem-Cell Transplantation Temporarily Improves Function and Health Status in RA Patients
New research helps delineate some of the benefits and potential limitations of high-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation in patients with severe refractory rheumatoid arthritis. Teng YK, et al. Arthritis Rheum. 2005;52:2272-2276.
Sunday Aug 07, 2005
Biogen Idec and PDL to Collaborate on Three Phase II Antibody Products
Biogen Idec of Cambridge, Massachusetts, and Protein Design Labs, Inc (PDL) of Fremont, California...
Monday Jun 13, 2005
IL-6 Blocker Shows Promise in Systemic Onset Juvenile Idiopathic Arthritis
More evidence emerging on the therapeutic potential of the experimental IL-6 blocker tocilizumab in the management of severe SJIA... Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Thursday Apr 07, 2005
FDA Orders Valdecoxib (Bextra) Withdrawn, Citing No Added Advantage
The agency also mandated black box warnings for celecoxib and stricter label warnings on traditional NSAIDs, including over-the-counter products... US Food and Drug Administration teleconference April 7, 2005.
Monday Apr 04, 2005
Analgesic Drug Pipeline, Though Relatively Dry, Poised for Revitalization
Despite a relative paucity in the current analgesic pipeline, a greater understanding of complex pain processes, pharmacogenetics, and new diagnostic tools and therapeutic targets, including assays and biomarkers, may open the doorway to more effective therapies, as well as better use of existing treatments...Presented at: 24th Annual Scientific Meeting of the American Pain Society; March 30-April 2, 2005; Boston, Mass.
Tuesday Mar 22, 2005
IL-6 Blocker "Promising" in Systemic Onset Juvenile Idiopathic Arthritis
Small study demonstrating efficacy and safety of MRA in juvenile arthritis, combined with promising results in treatment of other conditions, suggests that IL-6 inhibitors may play an important role in controlling inflammatory disease...Yokota S, et al. Arthritis Rheum. 2005;52:818-825.
Tuesday Dec 21, 2004
SLE Patients Treated with TNF-ÃŽalpha Blockade Show Improvement
Study indicates that TNF-alpha blocker may reduce SLE disease activity in patients' joints and kidneys, without serious adverse events; need for larger clinical trials cited... Aringer M, et al. Arthritis Rheum. 2004;50: 3161-3169.
|
